An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

Breast

Volumn 21, Issue 6, 2012, Pages 716-723

  Cardoso, Fatima ^a,h   Canon, Jean Luc ^b   Amadori, Dino ^c   Aldrighetti, Daniela ^d   Machiels, Jean Pascal ^e   Bouko, Yasmina ^f   Verkh, Lev ^f,i   Usari, Tiziana ^f   Kern, Kenneth A ^f   Giorgetti, Carla ^f   Dirix, Luc ^g  

^a JULES BORDET INSTITUTE   (Belgium)

^b Grand Hospital de Charleroi   (Belgium)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f PFIZER INC   (United States)

^g SINT AUGUSTINUS HOSPITAL   (Belgium)

^h Champalimaud Cancer Center   (Portugal)

ⁱ Stemedica Cell Technologies Inc   (United States)

Author keywords

Breast neoplasms; Docetaxel; HER2; Sunitinib; Trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; N DEETHYLSUNITINIB; SUNITINIB; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BREAST METASTASIS; CANCER RECURRENCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DERMATITIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; EXPLORATORY RESEARCH; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENERALIZED EDEMA; GINGIVA PAIN; GINGIVA ULCER; GINGIVITIS; GLOSSITIS; GLOSSODYNIA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMORRHOID; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; HYPERTENSION; INJECTION SITE REACTION; INTESTINE PERFORATION; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUTH DISCOMFORT; MOUTH PAIN; MOUTH ULCER; MUCOSA INFLAMMATION; MUCOSAL DRYNESS; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL BLISTER; OROPHARYNX PAIN; PALMAR ERYTHEMA; PALMAR PLANTAR ERYTHRODYSESTHESIA SYNDROME; PARESTHESIA; PERIPHERAL EDEMA; PLANTAR ERYTHEMA; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; SWELLING; THROMBOCYTOPENIA; TONGUE BLISTERING; TONGUE DISEASE; TONGUE EDEMA; TONGUE SWELLING; TONGUE ULCER; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; YELLOW SKIN;

EID: 84869205333     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.09.002     Document Type: Article

References (38)

1. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 2002, 20:1800-1808.
2. Tedesco K.L., Thor A.D., Johnson D.H., Shyr Y., Blum K.A., Goldstein L.J., et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. Journal of Clinical Oncology 2004, 22:1071-1077.
3. Marty M., Cognetti F., Maraninchi D., Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology 2005, 23:4265-4274.
4. Kuzur M., Albain K., Huntington M., Jones S., Hainsworth J., Greco F., et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proceedings of the American Society of Clinical Oncology 2000, 19. (abstr 512).
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001, 344:783-792.
6. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. Journal of Clinical Oncology 2011, 29:264-271.
7. Wardley A.M., Pivot X., Morales-Vasquez F., Zetina L.M., de Fátima Dias Gaui M., Reyes D.O., et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology 2010, 28:976-983.
8. Valero V., Forbes J., Pegram M.D., Pienkowski T., Eiermann W., von Minckwitz G., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of Clinical Oncology 2011, 29:149-156.
9. Metro G., Mottolese M., Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opinion on Pharmacotheraphy 2008, 9:2583-2601.
10. Mendel D.B., Laird A.D., Xin X., Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003, 9:327-337.
11. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical and Experimental Metastasis 2003, 20:757-766.
12. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Molecular Cancer Therapeutics 2003, 2:471-478.
13. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology 2008, 26:1810-1816.
14. Bergh J., Mariani G., Cardoso F., Liljegren A., Awada A., Viganò L., et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast 2012, 21:507-513.
15. Robert F., Sandler A., Schiller J., Liu G., Harper K., Verkh L., et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotheraphy and Pharmacology 2010, 66:669-680.
16. Nabholtz J.M., Tonkin K., Smylie M., Au H.J., Lindsay M.A., Mackey J. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?. Expert Opinion on Pharmacotheraphy 2000, 1:187-206.
17. -2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. British Journal of Cancer 1996, 74:650-656.
18. 2) as second-line monotherapy for non-small-cell lung cancer. Annals of Oncology 2004, 15:38-44.
19. Finkenzeller G., Weindel K., Zimmermann W., Westin G., Marme D. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis 2004, 7:59-68.
20. Konecny G.E., Meng Y.G., Untch M., Wang H.J., Bauerfeind I., Epstein M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clinical Cancer Research 2004, 10:1706-1716.
21. Klos K.S., Wyszomierski S.L., Sun M., Tan M., Zhou X., Li P., et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research 2006, 66:2028-2037.
22. Pegram M., Chan D., Dichmann R.A., Tan-Chiu E., Yeon C., Durna L., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Research and Treatment 2006, 100(Suppl 1):3039. [abstract].
23. ClinicalTrials.Gov. NCT00520975. Available from: http://clinicaltrials.gov/ct2/show/NCT00520975.
24. Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). San Antonio Breast Cancer Symposium; 2011 [abstract S4-8].
25. Sanofi-aventis Taxotere (docetaxel) prescribing information 2007, Sanofi-aventis, New York.
26. Rosing H., Lustig V., van Warmerdam L.J., Huizing M.T., ten Bokkel Huinink W.W., Schellens J.H., et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000, 45:213-218.
27. Leyland-Jones B., Gelmon K., Ayoub J.P., Arnold A., Verma S., Dias R., et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. Journal of Clinical Oncology 2003, 21:3965-3971.
28. Bruno R., Washington C.B., Lu J.F., Lieberman G., Banken L., Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemotheraphy and Pharmacology 2005, 56:361-369.
29. Harvey V., Mouridsen H., Semiglazov V., Jakobsen E., Voznyi E., Robinson B.A., et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. Journal of Clinical Oncology 2006, 24:4963-4970.
30. Chan S., Friedrichs K., Noel D., Pintér T., Van Belle S., Vorobiof D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology 1999, 17:2341-2354.
31. Inoue K., Nakagami K., Mizutani M., Hozumi Y., Fujiwara Y., Masuda N., et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Research and Treatment 2009, 119:127-136.
32. Michalaki V., Fotiou S., Gennatas S., Gennatas C. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. Anticancer Research 2010, 30:3051-3054.
33. Amoroso D., Donati S., Valsuani C., Puccetti C., Rondini M., Siclari O., et al. Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: first-step results of a phase II trial (HOT trial). Journal of Clinical Oncology 2009, 27(Suppl. 15). [abstract 1132].
34. Blay J, Lluch A., Gutierrez M., Martin M., Kozloff M., Prady C., et al. Sunitinib (SU) in combination with trastuzumab (T) for the treatment of advanced breast cancer (ABC): activity and safety results from a phase II study. Cancer Research 2009, 69(Suppl. 3). [abstract 201].
35. Crown J., Dieras V., Staroslawska E., Yardley D.A., Davidson N., Bachelot T.D., et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). Journal of Clinical Oncology 2010, 28(Suppl. 18). [abstract LBA1011].
36. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone - results of a prospective, randomized phase III study. Journal of Clinical Oncology 2012, 30:921-929.
37. Barrios C.H., Liu M., Lee S., Vanlemmens L., Ferrero J.M., Tabei T., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Research and Treatment 2010, 121:121-131.
38. Robert N.J., Saleh M.N., Paul D., Generali D., Gressot L., Copur M.S., et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clinical Breast Cancer 2011, 11:82-92.